한빛사 논문
Saad N. Mohammad a, Yeon Su Choi a, Jee Young Chung a, Edward Cedrone b, Barry W. Neun b, Marina A. Dobrovolskaia b, Xiaojing Yang c, Wei Guo c, Yap Ching Chew c, Juwan Kim d, Seunggul Baek d, Ik Soo Kim d, David A. Fruman e, Young Jik Kwon a,e,f,g
aDepartment of Pharmaceutical Sciences, University of California, Irvine, CA 92697, United States
bNanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, United States
cZymo Research Corporation, Irvine, CA 92604, United States
dPharma Research, Co, Ltd., Seongnam-si, Gyeonggi-do, Republic of Korea
eDepartment of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697, United States
fDepartment of Biomedical Engineering, University of California, Irvine, CA 92697, United States
gDepartment of Chemical and Biomolecular Engineering, University of California, Irvine, CA 92697, United States
Corresponding author: Young Jik Kwon
Abstract
Cancer-targeted therapy by a chemotherapeutic agent formulated in a nanoscale platform has been challenged by complex and inefficient manufacturing, low drug loading, difficult characterization, and marginally improved therapeutic efficacy. This study investigated facile-to-produce nanocomplexes of doxorubicin (DOX), a widely used cancer drug, and clinically approved DNA fragments that are extracted from a natural source. DOX was found to self-assemble DNA fragments into relatively monodispersed nanocomplexes with a diameter of ∼70 nm at 14.3% (w/w) drug loading by simple and scalable mixing. The resulting DOX/DNA nanocomplexes showed sustained DOX release, unlike overly stable Doxil®, cellular uptake via multiple endocytosis pathways, and high hematological and immunological compatibility. DOX/DNA nanocomplexes eradicated EL4 T lymphoma cells in a time-dependent manner, eventually surpassing free DOX. Extended circulation of DOX/DNA nanocomplexes, while avoiding off-target accumulation in the lung and being cleared from the liver, resulted in rapid accumulation in tumor and lowered cardio toxicity. Finally, tumor growth of EL4-challenged C57BL/6 mice (syngeneic model) and OPM2-challenged NSG mice (human xenograft model) were efficiently inhibited by DOX/DNA nanocomplexes with enhanced overall survival, in comparison with free DOX and Doxil®, especially upon repeated administrations. DOX/DNA nanocomplexes are a promising chemotherapeutics delivery platform for their ease of manufacturing, high biocompatibility, desired drug release and accumulation, efficient tumor eradication with improved safety, and further engineering versatility for extended therapeutic applications.
논문정보
관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기